Download Files:
Products Details
Product Description
– CDK9-IN-25 (compound 4a) is an imidazopyrazine CDK9 inhibitor (IC50: 0.24 μM). CDK9-IN-25 has good affinity to the main protease of COVID-19 and has antiviral activity against human coronavirus 229E (IC50: 63.28 μM)[1].
Web ID
– HY-155843
Shipping
– Room temperature
Molecular Formula
– C15H16FN5
References
– [1]Alsfouk AA, et al. New Imadazopyrazines with CDK9 Inhibitory Activity as Anticancer and Antiviral: Synthesis, In Silico, and In Vitro Evaluation Approaches. Pharmaceuticals (Basel). 2023 Jul 18;16(7):1018..
Molecular Weight
– 285.32
SMILES
– CC(C)(C)NC1=C(N=C2N1C=CN=C2)C3=CC(F)=NC=C3
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– 10 mM in DMSO
Target
– CDK;SARS-CoV;Virus Protease
Pathway
– Anti-infection;Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
